Actively Recruiting
Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock
Led by University Hospital, Clermont-Ferrand · Updated on 2026-04-29
750
Participants Needed
27
Research Sites
91 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Sepsis is a dysregulated host response to infection that leads to life-threatening organ dysfunction and represents a major healthcare problem. Septic shock is the most severe form, characterized by increased capillary permeability and vasodilation, resulting in hypotension and tissue hypoxia. Early identification and treatment of tissue hypoperfusion are pivotal components of initial resuscitation to limit progression to multiple organ dysfunction and death. The 2021 Surviving Sepsis Guidelines recommend guiding initial resuscitation by targeting decreases in serum lactate levels in patients with elevated lactate. However, although elevated lactate levels may reflect tissue hypoxia, serum lactate is not a direct marker of tissue perfusion. Hyperlactatemia may be attributable to mechanisms other than tissue hypoperfusion, such as accelerated aerobic glycolysis driven by excessive β-adrenergic stimulation or impaired clearance (e.g., in liver failure). The venous-to-arterial carbon dioxide partial pressure difference (CO₂ gap), which is inversely related to cardiac output, has been shown to reflect the adequacy of venous blood flow to remove CO₂ from tissues. The CO₂ gap is closely linked to microcirculatory blood flow during the early resuscitation phase of septic shock and may effectively identify persistent tissue hypoperfusion in shock states. A persistently high CO₂ gap during early resuscitation has been associated with significantly higher 28-day mortality and increased Sequential Organ Failure Assessment (SOFA) scores. Moreover, the CO₂ gap has been shown to respond to changes in cardiac output during inotrope infusion in patients with low blood flow, suggesting that its assessment could be useful for therapeutic adjustments. Therefore, there are compelling arguments to evaluate the usefulness of the CO₂ gap in guiding early resuscitation in patients with septic shock. The investigators postulated that CO₂ gap-guided early resuscitation may be more effective in improving outcomes than lactate-guided resuscitation.
CONDITIONS
Official Title
Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 years or older
- Acutely admitted to a study intensive care unit (ICU)
- Primary diagnosis of septic shock according to Sepsis-3 criteria
- Suspected or documented infection or positive blood culture
- Acute increase of at least 2 points in Sequential Organ Failure Assessment (SOFA) score due to infection
- Serum lactate level greater than 2 mmol/l
- Requirement of vasopressors (any dose of norepinephrine) to maintain mean arterial pressure of at least 65 mmHg despite adequate fluid resuscitation (minimum 1L intravenous fluid in last 24 hours prior to screening)
You will not qualify if you...
- Septic shock lasting more than 12 hours at screening
- Hypotension caused by reasons other than sepsis (e.g., acute bleeding)
- Decision not to resuscitate, limit care, or not intubate made before consent
- Imminent or inevitable death or life expectancy less than 3 months due to underlying disease
- Planned surgery within first 24 hours after randomization
- Refusal to participate by patient or relatives
- Participation in another randomized clinical trial that may affect the primary outcome
- Previous enrollment in this CARBON trial
- Known pregnancy
- Legal protection status preventing consent (e.g., incompetence without guardian, incarceration)
- No affiliation with the French health care system
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 27 locations
1
CHu Angers
Angers, France
Not Yet Recruiting
2
CH Aurillac
Aurillac, France
Not Yet Recruiting
3
CH de la Côte Basque
Bayonne, France
Actively Recruiting
4
CHU Bordeaux Hôpital Haut Lévèque
Bordeaux, France
Actively Recruiting
5
CHU Bordeaux Pellegrin Hospital
Bordeaux, France
Actively Recruiting
6
CHU Clermont-Ferrand Estaing
Clermont-Ferrand, France
Actively Recruiting
7
CHU Clermont-Ferrand Gabriel Montpied
Clermont-Ferrand, France
Actively Recruiting
8
CHU Dijon
Dijon, France
Actively Recruiting
9
CHU Grenoble
Grenoble, France
Not Yet Recruiting
10
CH Le puy en Velay
Le Puy-en-Velay, France
Actively Recruiting
11
HCL - Lyon Sud
Lyon, France
Not Yet Recruiting
12
HCL Hôpital Edouard Herriot
Lyon, France
Not Yet Recruiting
13
CHU Montpellier
Montpellier, France
Actively Recruiting
14
CH Moulins-Yzeure
Moulins, France
Not Yet Recruiting
15
CHU Nantes
Nantes, France
Actively Recruiting
16
CHU Nîmes
Nîmes, France
Not Yet Recruiting
17
APHP Beaujon
Paris, France
Actively Recruiting
18
APHP Bicêtre
Paris, France
Actively Recruiting
19
APHP La pitié Salpêtrière - Anesthésie et soin intensif
Paris, France
Actively Recruiting
20
APHP Lariboisière
Paris, France
Actively Recruiting
21
CHU la pitié slapêtrière - Anesthésie Réanimation
Paris, France
Actively Recruiting
22
CHU Poitiers
Poitiers, France
Actively Recruiting
23
CHU Rennes
Rennes, France
Actively Recruiting
24
CHRU Strasbourg - Service d'anesthésie-Réanimation médicale
Strasbourg, France
Actively Recruiting
25
CHU Strasbourg Service d'Anesthésie-Réanimation chirurgicale
Strasbourg, France
Actively Recruiting
26
Chu Toulouse
Toulouse, France
Actively Recruiting
27
CH Vichy
Vichy, France
Not Yet Recruiting
Research Team
L
Lise Laclautre
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here